Track Categories

The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.

Radiology is one of the branch of Medical Science that works on Medical imaging.
Radiology is divided into two sub-fields, diagnostic radiology and therapeutic radiology.
Diagnostic radiology uses various imaging modalities in the diagnosis of disease. In all the medical care fields’ diagnostic radiology plays important role in disease diagnosis.

Commonly used imaging modalities are:

  • General Diagnostic Radiology
  • Computed Tomography (CT)
  • CT Enterography
  • Magnetic Resonance Imaging (MRI)
  • Positron Emission Tomography (PET/CT)
  • Ultrasound
  • Nuclear Medicine
  • Nuclear Stress Test
  • CCTA - Coronary CT Angiography
  • Cardiac MR

In Vitro Diagnostics (IVD) are the medical devices, accessories, instruments, reagents and systems deployed to perform medical test on samples (e.g., blood, urine and tissue taken from human body) to diagnose diseases, detects infections, diagnose medical conditions, monitor drug therapies, prevent diseases. Some tests usually performed in authorized laboratories by the trained healthcare professionals and some tests can be done at home. Devices may range from simple tests to sophisticated DNA technology including calibrators, control materials, kits, reagents, software, or related instruments. IVD is an important segment in the global healthcare industry. The marketplace is witnessed rapid growth supported by advancements in technologies, evolvement of new tools, improvement in disease monitoring, higher demand of OTC tests, increased prevalence of infectious and other diseases like oncology, cardiovascular etc. IVD products are classified into Class I, III and III by FDA regulations to assure their safety and effectiveness. 

International Conference on In Vitro Diagnostics | Sep 03-04 | 2018 | London | UK | IVD Confereces | IVD Meetings | IVD Workshops | IVD Presentations | IVD instruments |US IVDs | CDx | VD Technology | diagnostics technologies | in vitro diagnostic research | in vitro diagnostic development | in vitro diagnostic manufacturers | point of care testing | in vitro diagnostics | clinical laboratory tests | assay system components | Medical Devices | Biomedical devices | Biomedical technologies | In vitro diagnostic multivariate index assay | Protein biomarkers | IVDMIA | IVD group | Who Global Model Regulatory Framework | Medical Devices | in Vitro Diagnostic Medical Devices | Who Medical Device | Immunochemistry Assay Development | Assay Development Service | Bioanalytical applications | Biomarkers | Biosensors | Blood gas analyser | Blood Glucose Meters | Blood Screening | Immunochemistry Assay Development | Assay Development Service | Bioanalytical applications | Biomarkers | Biosensors | Blood gas analyser | Blood Glucose Meters | Blood Screening | CE mark for IVD | Circulating tumor cell (CTC) | Clinical Evidence | Clinical Instruments | Clinical Microbiology | Compaliance | Companion Diagnostics | Custom Antibody | Data Management | Diagnosis | Diagnotics | Digital PCR | DNA testing | Enzyme Linked Immunosorbent Assay (ELISA) | Gene Diagnostics | Genetic Testing | Haematological diagnostics | Haemoglobin Meters | Hematological Diagnosis | Immuno assay | Immunoassay | Immunochemical labeling kits | In Vitro Diagnostics | In vitro diagnostics applications | In Vitro Diagnostics Devices | In vitro diagnostics Manufacturing | In vitro diagnostics technology | In Vitro diagnostics tests | Industry Classification | IVD Classifications | IVD Design | IVD devices | IVD Instruments | IVD Manufacturers | IVD Market Drivers | IVD Market Intelligence | IVD Market Landscape | IVD Market Reports | IVD Market Statistics | IVD Reagents | IVD Regulation | IVD Tests | IVDS | Lab | on | a | chip | Lateral flow assays | Liquid biopsy | Microarray technology | Microfluidics | Mobile healthcare | Molecular assays | Molecular Diagnostics | Nanomaterial | based assays | Next | generation sequencing (NGS) | Noninvasive prenatal testing (NIPT) | Oncology Diagnosis | Paper | based assays | Patient self | testing | PCR | POCT | Point of Care Diagnostics | Point | of | care | Post Market Surveillance | Precision Medicine | Primary antibodies | Q PCR | Quality Control | Quality system in IVD | Radioimmunoassay | Reagents | Regulatory affair | Secondary antibodies | Sepsis markers | Signal enhancement | Smartphone | based devices | Stroke markers | Surface plasmon resonance | UDI implementation | UL mark for IVD | Companion Diagnostics | Disease detection | Disease diagnosis | Disease prevention | DNA Microarrays | DNA testing | Electrochemistry | ELISA | Exosomes | Gene Expression | Genetic testing | Haematological diagnostics | Immuno assay | Immunoassays | In Vitro Diagnostics | In Vitro diagnostics tests | Infectious disease | IVD | Liquid biopsy | Micro Array | Molecular assays | Molecular assays | Molecular Diagnostics | NGS | PCR | POCT | Point of Care Diagnostics | RT PCR | Screening | IVD Product Manufacturers | Group Purchase Organizations (GPOs) | Original Equipment Manufacturers (OEM) | Pathologists and Pathology Laboratories | Distributors of IVD Products | Hospitals and Clinics | Healthcare Institutions | Research Institutes | Market Research and Consulting Firms | Reagents & Kits | Instruments | Services | Data Management Software | Clinical Chemistry | Basic Metabolic Panel | Electrolyte Panel | Liver Panel | Lipid Profile | Renal Profile | Thyroid Function Panel | Specialty Chemical Tests | Immunochemistry/Immunoassay | Enzyme-Linked Immunosorbent Assay (ELISA) | Chemiluminescence Immunoassay (CLIA) | Fluorescence Immunoassay (FIA) | Colorimetric Immunoassay (CI) | Radioimmunoassays (RIA) | Rapid Tests | Western Blot | ELISPOT | Hematology | Coagulation & Hemostasis | Clinical Microbiology | Molecular Diagnostics (MDx) | Polymerase Chain Reaction (PCR) | Isothermal Nucleic Acid Amplification Technology (INAAT) | Microarrays | Hybridization | DNA Sequencing & Next-generation Sequencing | Other MDx technologies | Other Technologies | Global In Vitro Diagnostics Market | by Application | Diabetes | Infectious Diseases | Oncology/Cancer | Cardiology | Nephrology | Autoimmune Diseases | Drug Testing | HIV/Aids | Other Applications | Global In Vitro Diagnostics Market | by End User | Hospitals | Laboratories | Academic Institutes | Point-Of-Care Testing | Patient Self-Testing | End Users | immunoassays | point of care | molecular diagnostics | hematology | coagulation | microbiology | clinical techniques | microbiology | nstruments | reagents | services | data management systems | diabetes | oncology | cardiology | HIV/AIDS | autoimmune disease | nephrology | drug testing | IVD market | clinical laboratory testing | near-patient testing | self-testing | Prognosis of prediabetes and diabetes | Prediction of gestational diabetes | Treatment selection and monitoring | Guide development of islet sparing | disease-modifying drugs | Companion diagnostics | Direct assessment of pancreatic islet health | Improved efficiency and convenience compared to oral glucose test | Measurements complementary to glycemia | Early diagnosis of pheochromocytomas and other NET in plasma. | Accurate prognostic assessment | in vitro diagnostics | immunoassays | lateral flow assays | nanomaterial-based assays | biomarkers | lab-on-a-chip | microfluidics | electrochemistry | biosensors | signal enhancement | surface plasmon resonance | microarrays | paper-based assays | smartphone-based devices | mobile healthcare | point-of-care | bioanalytical applications | Antigen | AP (Alkaline Phosphatase) | Array | Assay diluent | Assay sensitivity | BCIP | Blocking | Blotting | Chemiluminescent substrate | Clinical sensitivity | Clinical specificity | Colorimetric substrate | Conjugate | Cross-reactivity | Detection limit | Diagnostic assay | Dilution | Dynamic range | ELISA (Enzyme-Linked ImmunoSorbant Assay) | Enzyme | Heterophilic interference | HRP (Horseradish Peroxidase) | Immunoassay | Immunoblotting | Immunohistochemistry | In situ hybridization (ISH) | Interference | IVD (In Vitro Diagnostics) | Matrix effect | Membrane | Microwell | Molecular diagnostics | Multiplexing | Non-specific binding | Passivating surface chemistry | pNPP | Protein stabilizers | Rheumatoid factor | Sample matrix interference | Signal | Substrate | Test performance | TMB | Western Blot | ID/AST Test | Auto ID | AST Systems | Manual ID | AST Systems | Blood Culture | Chromogenic Media | Rapid Micro,ID/AST Leader Market | Infectious Disease Immunoassays | Lab-Based | POC | Home Testing | Laboratory Infectious Disease | Immunoassays Sales by Disease,Hepatitis | HIV | Mycology | Parasitology | Respiratory | Sepsis | STDs | ToRCH | Infectious Disease Diagnostic Sales– North America | Western Europe | Japan | China | India | Latin America | ROW | Blood Screening Test Market Size and Company Market Share | Worldwide Cancer Diagnostic Market | Global Cancer IVD Market | Clinical Laboratory Services | Marketing Screening Tests for Prostate Specific Antige | Regulatory Strategy Expertise | FDA Negotiation | Clinical Trial Protocol Development | Clinical Site Recruitment | Clinical Trial Management | Statistical Planning and Analysis | Final Clinical Trial Reports | Regulatory Submissions | Quality Manufacturing Audits | Broad Selection of Clinical Diagnostic Analyzers | Abbott IMX | Abbott AxSym Plus | Abbott Architect | | Roche ElecySys 2010 | Siemens/Dade RXL | Tosoh AIA-600-II | Complement of Molecular Diagnostic Techniques | Full suite of CLSI Testing required by FDA-OIVD | IVD Test Technology Evaluation & Optimization | IVD Test Development & Optimization | Association of Medical Diagnostic Manufacturers | American Association for Clinical Chemistry | U.S. Food and Drug Administration | Clinical and Laboratory Standards Institute | Cancer Markers & PGx | Histology (In situ hybridization | HPV) | Microbiology/Virology (HAI; HIV; Hepatitis; GC/Chlamydia; Respiratory;Organism ID; Mycobacteria | TB; Others) | Blood Screening | Coagulation & PGx | Prenatal Testing | Inherited Diseases Testing | Tissue Typing | Organ Transplant Testing (HLA Typing) | Circulating Tumor Cells (CTCs) | Clinical Sequencing | Flow Cytometry | Cancer IVD Market | Cancer Test Services Market | Sequencing in Cancer Testing | Tissue Function Tests | PSA | CEA and Other Immunoassays | Flow Cytometry | Pap and HPV Testing | FOB and Other Rapid Tests | Molecular Oncology Assays | Tissue Microarrays | Methylated DNA | In situ hybridization (ISH) | Immunohistochemistry (IHC) | Circulating Tumor Cells | Companion Testing and CDX Products | Chromosome Analysis (Karyotyping) | Cytology/Histology Stains | Tests for Fecal Occult Blood | Immunoassays | Overview - Immunoassays | Immunoassay Instrument Platforms | Immunohistochemistry (IHC) | Flow Cytometry | Fluorescence in situ Hybridization (FISH) and Chromogenic in situ Hybridization(CISH) | Nucleic Acid Amplification Technologies | Analysis of Gene Expression Patterns (Gene Signatures) | Microarrays | Protein Microarrays | DNA Microarrays | Chromosomal Microarrays | Tissue Microarrays | Sequencing Technologies | Sanger Sequencing | Early Next Generation Sequencing Technologies | Sequencing by Synthesis (SBS) | Supported Oligonucleotide Ligation and Detection (SOLiD) | Ion Torrent Sequencing | True Single Molecule Sequencing (tSMS) | Single Molecule Real Time (SMRT) Sequencing | DNA Nanoball Sequencing | Nanopore Sequencing | Other Sequencing Technologies | Mass Spectrometry | Mass Spectrometry Technology | Research and Clinical Applications of Mass Spectrometry | Circulating Tumor DNA (Cell Free DNA) | Circulating Tumor Cells (CTCs) | Cell-Based Assays (Live Cell Cancer Tests) | Digital Pathology and Image Cytometry | Information Technology | Assess Risk of Developing Cancer | Cancer Screening | Cancer Screening – Pap Smear and Human Papillomavirus (HPV) Testing | Colorectal Cancer Screening | Prostate Cancer Screening | Screening for Other Cancers | Diagnosis/Prognosis/Monitoring of Cancer | Personalized Medicine/Companion Diagnostics/Precision Testing | Drug Metabolism | Predicting Response to Therapy | FIVE: CANCER DIAGNOSTIC MARKETS | In Vitro Diagnostic Kits Marketed to Clinical Laboratories | Point-of-Care Tests for Cancer | Clinical Laboratory Test Services | Investments and Financing Agreements for Cancer Diagnostic Companies | Agreements with Other Companies | Acquisitions of Cancer Diagnostic Companies | Selected Other Agreements | Cancer Diagnostic Market Drivers | Advances in Technology Changing the Future of Cancer Diagnostics | Impact of Companion Diagnostic Tests | Limited Tissue from Biopsies for Growing Number of Cancer Tests | Laboratory Developed Tests and the FDA | Cost and Reimbursement Issues | Physician Education | Acceptance | and Use of New Cancer Tests | Competition | Future Prospects | In Vitro Cancer Diagnostics Market by Geographical Distribution | Clinical Laboratory Testing Market – Cancer Diagnostics | In Vitro Cancer Diagnostics Market Segments | Histology/Cytology | Immunoassays | Rapid Tests | Molecular (Nucleic Acid-Based) Assays | M Genomics Ltd. | 20/20 GeneSystems | Inc. | AB SCIEX | Abbott Laboratories | Abcodia Ltd. | Abingdon Health Ltd | Abnova Corporation | ACT Genomics Co. | Ltd. | Adaptive Biotechnologies Corporation | Admera Health (a GENEWIZ company) | Advanced Cell Diagnostics | Affymetrix | Inc. | Agena Bioscience Inc. | Agendia NV | Agilent Technologies Inc. | Alere Inc. | Ambry Genetics Corp. | Amoy Diagnostics Co. | Ltd. | ANGLE plc | ApoCell | Inc. | Applied Proteomics | Inc. | Applied Spectral Imaging | Inc. | Arbor Vita Corporation | ARKRAY | Inc. | ARUP Laboratories | Astra Biotech GmbH | Asuragen | Inc. | AsymmetRx Medical | Inc. | Atossa Genetics Inc. | AutoGenomics | Inc | Avant Diagnostics | Inc. (formerly Arrayit Diagnostics Inc.) | Axela | Inc | AXO Science | Beckman Coulter | Inc. (subsidiary of Danaher Corporation) | Becton | Dickinson and Company (BD) | BGI-Shenzhen | The Binding Site Group Ltd. | Biocare Medical | LLC | Biocartis SA | Biocept | Inc. | Biodesix | Inc. | BioFluidica | BioGenex | Biological Dynamics Inc. | BioMarker Strategies | bioMérieux SA | BioMosaics | Bio-Rad Laboratories | Inc. | Bio-Reference Laboratories | Inc. (BRLI) | BioSystems | bioTheranostics (a bioMérieux company) | Biotype Diagnostic GmbH | BioView Ltd | Boditech Med Inc. | Cancer Genetics | Inc. | Canopus Bioscience Ltd. | Caprion | Inc. | Caris Life Sciences | Castle Biosciences | Inc. | CDx Diagnostics | Celerus Diagnostics | Inc. | Cellmid Ltd. | Centogene AG | Cepheid | Cernostics | Cirdan Imaging Ltd | Clarient Diagnostic Services | Inc. (a GE Healthcare company) | Clearbridge BioMedics Pte Ltd | Color Genomics | Inc. | Counsyl | Inc. | Cube Dx GmbH | Cynvenio Biosystems | Inc. | CytoTest Inc. | Dako A/S (an Agilent company) | Danaher Corporation | DermTech | Inc. | DiaCarta | Inc. | DiaSorin S.p.A. | DiaTech Oncology | EDP Biotech Corporation | Eiken Chemical Co. | Ltd. | EntroGen | Inc. | Enzo Biochem | Inc | Enzo Life Sciences | Inc. | Enzo Clinical Labs | Inc. | Epic Sciences | Inc. | Epigenomics AG | Eutropics Pharmaceuticals | Exact Sciences Corporation | Exosome Diagnostics | Inc. | Fluxion Biosciences | Inc. | Foundation Medicine | Inc. | Fujirebio Inc. | Fujirebio Diagnositics | Inc. | GE Healthcare | Genalyte | Inc. | GeneCentric Diagnostics | Inc. | Genection | Inc. (an Invivoscribe company) | GeneDx | GeneNews Limited | Genetic Technologies Limited / Phenogen Sciences | Inc. (U.S. division) | GenomeDx Biosciences | Genomica S.A.U. | Genomic Health | Inc. | Genomic Vision | Genoptix (a Novartis company) | GenPath / GenPath Women’s Health and GenPath Oncology | Guardant Health | Inc. | HalioDx | Healgen Scientific LLC | Helomics Corporation | Hologic | Inc. | HTG Molecular Diagnostics | Inc. | Human Longevity | Inc. | Icellate AB | Ikonisys | Inc. | Illumina | Inc. | ImCare BioTech | Immunovia AB | IncellDx | Inc. | Inform Genomics | Inc. | Financings | Other Agreements | Inivata Ltd. | Innovations Exchange Pte Ltd (INEX) | Insight Genetics | Inc. | IntegraGen SA | Integrated Diagnostics | Inc. | Invitae Corporation | Invivoscribe Technologies | Inc. | Iris BioTechnologies Inc. | Janssen Diagnostics / Janssen Diagnostics BVBA | Janssen Diagnostics | LLC | Laboratory Corporation of America (LabCorp) / Integrated Genetics | Leica Biosystems Inc. (a Danaher company) | Leica Microsystems (a Danaher company) | Lifecode | Inc. | MagArray | Inc. | Martell Diagnostic Laboratories | Inc. | Matrix-Bio | Inc. | Mayo Medical Laboratories and Mayo Clinic | Medical & Biological Laboratories Co. | Ltd. (MBL) | MBL International Corporation | MDxHealth SA | Metamark Genetics | Inc. | MetaStat | Inc. | MolecularMD Corporation | Multiplicom NV | Myriad Genetics | Inc. | Myriad RBM | Inc. | NanoIVD | Inc. | NanoString Technologies | Inc. | NeoGenomics | Inc. / NeoGenomics Laboratories | NewGene Ltd. | New Oncology AG | Nuclea Biotechnologies | Inc. | Ohmx Corporation | Omnyx | Oncimmune Ltd. | Oncimmune (USA) LLC (acquired by HDL Inc.) | Health Diagnostic Laboratory | Inc. | OncoCyte Corporation | OncoDNA SA | OncoHealth Corp. | Oncolab | Inc. | Oncolys BioPharma Inc. | Oncompass GmbH | Onconome | Inc. | OncoPlex Diagnostics (OncoPlexDx) | Oncospire Genomics | OPKO Health | Inc. / OPKO Diagnostics | Orion Genomics | Ortho-Clinical Diagnostics | OvaGene Oncology Inc. | Oxford Cancer Biomarkers Ltd. | Oxford Gene Technology | Pacific Edge Limited | Pathway Genomics Corporation | Personal Genome Diagnostics | Inc. | PGXL Laboratories | Phenomenome Discoveries Inc. | Polymedco | Inc. | PreTect AS | PrognosDx Health | Inc. | Provista Diagnostics | Inc. | QIAGEN N.V. | QuanDx | Quanterix Corporation | QuantuMDx Group | Quest Diagnostics | RainDance Technologies | Inc. | Randox Laboratories Ltd | Rarecells SAS | Response Genetics | Inc. | Rheonix | Inc. | RiboMed Biotechnologies | Inc. | Roche | Rosetta Genomics Ltd. | ScheBo-Biotech AG | ScreenCell | Sequenom | Inc. | Siemens Healthcare Diagnostics | Symbiodx | Sysmex Corporation | TeloVISION | LLC | Theranostics Health Inc. | Thermo Fisher Scientific | Inc. | Tosoh Corporation | Tosoh Bioscience | Inc. | Transgenomic | Inc. | TrimGen Corporation | TrovaGene | Inc. | Vela Diagnostics | Ventana Medical Systems | Inc. (member of the Roche Group) | Veracyte | Inc. | Wako Diagnostics | Wako Pure Chemical Industries | Ltd. | | Abbott Diagnostics | IntelligentMDx Alliance | PLEX-ID | Iridica | Histology | Alere Inc. | Beckman Coulter | Inc. / Danaher | Lab Services | Sequencing | Genomics | Information Technology | Becton | Dickinson and Company (BD) | The BD MAX Enterprise | Oncology | HPV | Sequencing | Initiatives | Mass Spectrometry | Flow Spectrometry | Bio-Rad Laboratories | Inc. | Controls | Digital PCR | bioMérieux Inc | Expansion | Oncology | Molecular Strategy | Sequencing Service | Danaher Corporation | General Electric - GE Healthcare | Clarient Diagnostic Services | Inc. | Hologic | Inc. | Product News | The Gen-Probe Business | Panther System | Blood Bank | Quest Contract | QIAGEN N.V. | Personalized Healthcare | Infectious Disease Testing | Transplant Medicine and HAIs | HPV | Companion Diagnostics | Liquid Biopsy/CTC | Instrumentation Base | Rotor-Gene Q – Clinical Diagnostics | Sequencing | Exosomes | Information Technology | Collaborations | Forensics | Roche Diagnostics | New Enterprises | Global Access Program for HIV | Core Molecular Tests | STDs | A POC Enterprise – Liat | Prenatal and cfDNA | HPV | Blood Bank | Liquid Biopsy | Sequencing – Putting the Pieces Together | Siemens Healthcare Diagnostics | Histology | Molecular | Companion Diagnostics | Sequencing | China | Sysmex Corporation | Inostics GmbH | Intraoperative Test | Flow Cytometry | Thermo Fisher Scientific Inc. | Molecular Microbiology | Microbiology IT | Transplant | Quality Control | Mass Spectrometry | EIGHTEEN: COMPANY PROFILES: MAJOR MOLECULAR COMPANIES | Affymetrix Inc. | Agilent Technologies | Agilent in Genomics | PCR | Sequencing | Arrays | Sample Management | Mass Spectrometry | Expansion | Asuragen Inc. | Controls | Sample Collection | Sequencing | BGI | With Complete Genomics | BGI Projects | Cepheid | Hospital Acquired Infections (HAI) | TB | Infectious Diseases | Virology | Oncology | Eiken Chemical Co. | Ltd | Enzo Biochem Inc. | IP Situation | Illumina | Sequencing | Sequencing Kits | Sample Prep | IVD Business | Oncology | HLA Typing | IT | Forensics | CLIA Lab Service | Nanopore Sequencing | Sample to Insight | Making a Market | IP Situation | Life Technologies Corporation | Instrumentation and Applications | Liquid Biopsy | Sequencing | Life Technologies an IVD Company | Partnerships Worldwide | Life and Quidel Develop Diagnostics on the 7500 Fast Dx | Sepsis | HIV | Emerging Pathogens | Bacterial Typing | Personalized Medicine | Forensic | PerkinElmer | Inc. (PE) | Newborn Testing | Prenatal Testing | Sequencing | Mass Spectrometry | Information Technology | China | RainDance Technologies | Inc. | Market Expansion | NINETEEN: COMPANY PROFILES: PARTICIPANTS | AutoGenomics Inc. | Biocartis SA | Connectivity | Instrumentation | Collaborations | Idylla News | DiaSorin S.p.A | EKF Diagnostics Holdings Plc | ELITech Group | Epigenomics | Exosome Diagnostics | Inc. | Fluidigm Corporation | Fujirebio Diagnostics | Inc. | GenMark Diagnostics | Genome Diagnostics BV (GenDx) | Luminex Corporation | Business Expansion | MAGPIX Multiplexing | Next Generation NxTag | Product News | Menarini Diagnostics | Nanostring Technologies | Inc. | Alliances | LDTs | Pacific Biosciences of California | Inc. (PacBio) | Quidel Corporation | Lyra Product Line | Solana Molecular System | AmpliVue Product Line | Savanna (formerly Wildcat) | Acquisitions | Rubicon Genomics | Inc. | Transgenomic | Inc. | Alliances | Lab Services | Diagnostic Tools Division | TrovaGene | Inc. | WaferGen Bio-systems | Inc. | TWENTY: COMPANY PROFILES: GREAT EXPECTATIONS | Genomic Vision | GENOMICA S.A.U. | IncellDx | Inc. | Inivata | IntegenX Inc | Linkage Biosciences | Inc. | Savyon Diagnostics | Selventa | VolitionRx Limited | TWENTY-ONE: COMPANY PROFILES: NEWCOMERS | B Braun CeGaT | LLC | Canon BioMedical | Inc. | DestiNA Genomics Ltd | DiamiR | LLC | Randox Laboratories Ltd. | TWENTY-TWO: COMPANY PROFILES: TEST SERVICE PROVIDERS | 23andMe | What a Difference a Few Years Makes | The Move to Building a Research Company | Therapeutics Group | Ancestry | Outside the U.S. | Adaptive Biotechnologies Corporation | Agendia BV | AltheaDx Diagnostics | Inc. | Ambry Genetics | Oncology | Cardiac | Prenatal | Information Technology | ARUP Laboratories | Assurex Health | Athena Diagnostics | Bio-Reference Laboratories | Inc. (BRLI) | bioTheranostics | Cancer Genetics | Inc. (CGI) | The Response Genetics Acquisition | CareDx | Inc. | Caris Life Sciences | Centogene AG | Complete Genomics | Counsyl | Exact Sciences Corp. | Foundation Medicine Inc. | Genomic Health | Inc. | Market Uptake | Sequencing | Liquid Biopsy | Service Spin Off | Helomics Corporation | IntegraGen | Invitae Corporation | LabCorp | Laboratory Corporation of America | Infectious Diseases | Prenatal | Sequencing | Oncology | BRCA Saga | Information Technology | Forensic | Collaborations | Mayo Medical Laboratories | Information Technology | MDxHealth SA | Myriad Genetics | Product News | Companion Tests | Beyond Cancer | The U.S. Market | IP Update | Pathway Genomics Corporation | Quest Diagnostics | Oncology | Toxicology | Prenatal and Women’s Health | Market Expansion | Quest Partners for Market Accessibility | Rosetta Genomics Ltd. | Expansion | Veracyte | Inc. | TWENTY-THREE: COMPANY PROFILES: POINT OF CARE TEST SPECIALISTS | Atlas Genetics Ltd. | Biomeme | Inc. | DiAssess Inc | DNA Electronics Ltd (DNAe) | Enigma Diagnostics Limited | Entopsis | Epistem Holdings plc | InSilixa Inc. | Lucigen | PositiveID Corporation | QuantuMDx Group Limited | Rheonix | Inc. | Scanogen Inc. | Ubiquitome | Veredus Laboratories Pte Ltd | Xagenic

  • Track 2-1: infectious Disease testing options: Respiratory Diseases, Gastrointestinal Diseases, and Bloodstream Infections etc.
  • Track 2-2: Molecular Genetics in diagnosis of haematological malignancies
  • Track 2-3: Screening, Prevention, Early detection: Cancer, Infectious diseases, healthcare-associated infections (HAI), Antimicrobial resistance (AMR), Diabetes, Genetic diseases, and Rare diseases
  • Track 2-4: Diagnosis: Diabetes, Sexually Transmitted Diseases (STDs), Infectious diseases, Cholesterol, Heart Disease, Pregnancy, Allergy, Immunology Renal disease
  • Track 2-5: Prognosis: Cancer, HIV, Heart disease Immunology, and Sepsis
  • Track 2-6Monitor Treatment Performances: Diabetes, Anticoagulation, Antibiotics, and Viral load

Point-of-care testing (POCT) are the medical tests that are performed by trained healthcare professionals at or near the site of patient. Main POCTs include blood and urine tests. POCT is aimed to collect specimen and get accurate results in a very short span of time. POCTs are mainly used in primary care, secondary care and community care based settings. POCT are performed via portable instruments such as blood glucose meter, blood gas, pH, electrolyte and metabolite and haemoglobin measurement meters.

A companion diagnostic is a medical device/ diagnostic test/ imaging tool, used companion to drugs and provides information regarding the applicability of drug or biologics to a specific person. It helps the healthcare professionals to determine whether the product will be beneficial to the patients or will have any risks or side effects.

Molecular Diagnostics is a collection of various techniques that are used to analyse biological markers in the proteome and genome and how their cells expressed the genes by the application of molecular biology to genetic testing. Globally the use of Molecular diagnostics growing rapidly. Major clinical applications are in the areas of oncology, infectious disease, genetic diseases, pharmacogenomics, human leukocyte antigen typing; and coagulation.

Last five decades has seen a tremendous growth in Immunodiagnostics tests and it emerged as a potential diagnostic technique.  The radioimmunoassay and Enzyme Linked Immunosorbent Assay (ELISA) were the predominant techniques during the initial era of Imunodiagnostics.

  • Track 3-1: Current trends, Future Market, Issues & Challenges:
  • Track 3-2: Point of Care Diagnostics (POCs)
  • Track 3-3: Companion Diagnostics
  • Track 3-4: Molecular Diagnostics
  • Track 3-5: Immunodiagnostics
  • Track 3-6: Hematological Diagnosis
  • Track 3-7: Clinical Chemistry
  • Track 3-8: Microbial Applications

In vitro fertilization (IVF) treatment is mind boggling arrangement of methodology utilized for richness treatment or hereditary issues and help with the origination of a youngster. Amid in vitro preparation, develop eggs were gathered from ovaries and treated by sperm in a lab conditions. In vitro treatment is the best type of helped regenerative innovation. Amid in vitro preparation, eggs and sperm are united in research facility glass dish to enable the sperm to treat an egg. Utilizing as a part of vitro preparation, one can utilize any mix like claim eggs and sperm or giver eggs and sperm. After in vitro preparation, at least one treated eggs are put in the uterus.

Noninvasive prenatal testing (NIPT), Liquid biopsy, Next-generation sequencing (NGS), and circulating tumor cell (CTC) tests etc. are considered as the future of the In Vitro Diagnostics (IVD). These areas of the IVD market is expected to witness a rapid growth in coming few years. In coming five years, the cost of NGS test will rise from $250 million to $800 million with the total number of NGS sales only rise from 100 million to 300 million. Though globally, the growth of IVD market is stagnant, it is predicted that NIPT will grow at a rate of 20% in USA and even more in abroad. Other future IVD devices include point of care biochemistry analyser (eg. Abbott i-STAT) blood gas analyser (eg. biosurfit spinit), immunology, haematology, and clinical chemistry analyser (eg. Acon Blood Glucose,  Total Cholesterol, Cholesterol 3-1,  Haemoglobin Meters and Hemoccult), and FOB test.

  • Track 5-1: Microarray technology
  • Track 5-2: Noninvasive prenatal testing (NIPT)
  • Track 5-3: Next-generation sequencing (NGS)
  • Track 5-4: Liquid biopsy
  • Track 5-5: Circulating tumor cell (CTC) tests
  • Track 5-6: High value-added polymerase chain reaction (PCR), Digital PCRs & Q-PCRs
  • Track 5-7: Point of care biochemistry analyser
  • Track 5-8: Blood gas analyser, Total Cholesterol, blood glucose and Haemoglobin Meters
  • Track 5-9: Immunology and clinical chemistry analysers
  • Track 5-10: Sepsis markers, Stroke markers and DNA testing

The US Food and Drug Administration (FDA) is involved in the regulation of IVDs or laboratory tests after the inception of the Medical Device Amendments of 1976. According to the guidelines of the FDA, IVD products are classified into Class I, II, or III which is based on the level of regulatory control that is essential to ensure the safety and effectiveness of devices. The Code of Federal Regulations lists the classification of existing IVDs in 21 CFR 862, 21 CFR 864, and 21 CFR 866. CLIA '88 is responsible for the quality standards of laboratory testing and an accreditation program for clinical laboratories. In the EU market, the In Vitro Diagnostics Directive (IVDD) 98/79/EC is the main regulatory requirements that medical device manufacturers comply with to get a CE marking in their products.

  • Track 6-1: IVD regulations in the USA, EU, Asia and Middle East
  • Track 6-2: Updated ISO 13485:2016 towards the QMS requirements of IVDR
  • Track 6-3: Compliance issues with Post Market Surveillance
  • Track 6-4: POCT policy and Reporting Issues
  • Track 6-5: Classifications of IVD & Requirements of IVD labelling
  • Track 6-6: Good Manufacturing Practices (GMPs) , Quality System Regulations (QSRs) and Medical Device Listing
  • Track 6-7: European requirements for CE marking

As one of the fastest-growing areas of In vitro diagnostics, Oncology testing to become an $8 billion market in 2018. It is not surprising that the most strenuous efforts in medical science are aimed at the no.2 killer disease. Oncology killed more than 7 million people worldwide in 2010, which is more than AIDS, massslaria, and tuberculosis combined. It is second heart leading disease-causing death across the globe.  Annual Oncology deaths would reach13.2 million by 2030.An important step in oncology testing is digital imaging that eliminated human stained-tissue slide reading.

  • Track 7-1: Molecular Diagnostic Tests of Cancer Diagnosis: Sequencing in Cancer Testing, Tissue Function Tests, PSA, CEA and Other Immunoassays, Flow Cytometry, Pap and HPV Testing, FOB and Other Rapid Tests, Molecular Oncology Assays, Tissue Microarrays, Methylat
  • Track 7-2: Early Diagnosis and Treatment of Cancer
  • Track 7-3: Application and role of NGS in Cancer Diagnosis
  • Track 7-4: Liquid biopsy in cancer detection, diagnosis and monitoring
  • Track 7-5: Proteomic technologies for early detection of cancer
  • Track 7-6: Circulating Tumour Cells (CTC) in cancer predication
  • Track 7-7: Precision Medicines for Oncology

Infectious diseases are disorders that are caused by various organisms like bacteria, viruses, fungi or parasites. They are transmitted through contaminated foods and through physical contacts. Infectious diseases such as hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), Herpes Simplex Virus (HSV), tuberculosis, measles, dengue, Chagas, cholera, and malaria are increasing across the globe, mostly in developing countries.

In Vitro Diagnostics (IVDs) help in identifying the pathogenic agent such as bacteria, viruses or fungi that are responsible  infectious diseases and alo helps to select the appropriate treatment options. Molecular Diagnostics Tests also helps to perform both targeted and syndromic Clinical Tests for Infectious Diseases resulting the incresing demands.

As per a research it is found that the Global IVD Infectious Disease market is anticipated to hit $25.9bn by end of the year 2022. Major drivers of the IVD market for the Infectious Disease are launch of new advanced Diagnostics Devices, rapid growth of infectious disease, accuracy and cost effectiveness of the Diagnostics Devices etc. 

 

  • Track 8-1: Molecular Diagnostics Testing
  • Track 8-2: Molecular Diagnostics in Infectious disease
  • Track 8-3: Anti-microbial resistance (AMR) and Point of Care Testing (POCT)
  • Track 8-4: Rapid diagnosis in acute care: influenza, pneumonia etc.
  • Track 8-5: Diagnostic monitoring of adenovirus infections
  • Track 8-6: Point of care testing (POCT) for infectious diseases
  • Track 8-7: PCR assays in diagnosing Multi Drug Resistant (MDR) pathogens

Cardiovascular ailment (CVD) is a class of infections that include the heart or veins. Cardiovascular sickness incorporates coronary corridor infections (CAD, for example, angina and myocardial dead tissue (usually known as a heart assault). Different CVDs incorporate stroke, heart disappointment, hypertensive coronary illness, rheumatic coronary illness, cardiomyopathy, heart arrhythmia, inherent coronary illness, valvular coronary illness, caritas, aortic aneurysms, fringe corridor sickness, thromboembolic infection, and venous thrombosis.

Diabetes, is likewise knows as diabetes mellitus, is a gathering of metabolic issue where high glucose levels over a drawn-out period found. Side effects of high glucose incorporate regular pee, expanded thirst, and expanded appetite. They are two sorts of diabetes: Type1DM, comes about because of insulin inadequacy, and Type2DM, comes about because of insulin protection and gestational diabetes that outcomes from pregnant ladies with medicinal history of diabetes.

Traditional biosensors like glucose meters and glycohemoglobin test kits are commonly used for In Vitro Diagnosis of the disease and long-term management of diabetes. The increasing prevalence of diabetes and the demand for the diagnostic tests helps to drive the market and to go for new R&D in this sector to develop innovative products.Other Point of Care Tests such as HbA1c are preferred due to their capability of Rapid Diagnosis and management of diabetes with a reduced cost.  

  • Track 9-1: Cardic Markers for in diagnosis and monitoring
  • Track 9-2; Cardiac Biomarkers: CK-MB, Troponin, Myoglobin, Myeloperoxidase (MPO), Brain natriuretic peptide (BNP), proBNP, high sensitive Creactive protein (hsCRP), homocysteine, Fatty Acid Binding Protein (FABP), Glycogen Phosphorylase isoenzyme BB (GPBB), urinar
  • Track 9-3: Point-of-Care (POC) test in cardiovascular diseases
  • Track 9-4: Diagnostic screening using IVD and diagnostic imaging technologies
  • Track 9-5: Challenges in Diagnosis improvement
  • Track 9-6: Future of Cardiovascular Diagnostics

Nephrology is a claimed to fame of pharmaceutical and paediatrics that frets about the kidneys: the investigation of ordinary kidney capacity and kidney issues, the conservation of kidney wellbeing, and the treatment of kidney issues, from eating routine and medicine to renal substitution treatment (dialysis and kidney transplantation). Fundamental conditions that influence the kidneys, (for example, diabetes and immune system malady) and foundational issues that happen in view of kidney issues, (for example, renal osteodystrophy and hypertension) are additionally examined in nephrology. A doctor who has attempted extra preparing to wind up plainly a specialist in nephrology may call themselves a nephrologist or renal doctor. IVD methodologies help in rapid diagnostics of Nephrological disorders and shown a new avenue. 

  • Track 10-1: Diagnostic tests to detect renal function
  • Track 10-2: Renal Biomarkers
  • Track 10-3: Next-generation sequencing (NGS) in diagnostics of kidney disease

An IVD Medical Device defined as a device which, whether used alone or in combination for the in-vitro examination of specimens derived from the human body solely or principally to give information for diagnostic, monitoring or compatibility purposes. Biomarkers can be a substance used for examining organ function and condition. There are two major types of biomarkers: biomarkers of exposure, that are used in risk prediction, and biomarkers of disease, that are used in screening, diagnosis and monitoring of disease progression. Additional potential of molecular biomarkers is to identify individuals susceptible to disease. Examples of Biomarkers body temperature for fever, cholesterol for heart stroke, C-reactive protein for inflammation.

  • Track 11-1: Roles of Biomarkers in IVD
  • Track 11-2: Challenges in new marker & technologies
  • Track 11-3: Role of Biomarkers in personalized treatment of Cancer
  • Track 11-4: Biomarkers in Early Cancer Diagnosis
  • Track 11-5: Role of Prognostic biomarkers
  • Track 11-6: Diagnostic Biomarkers in cancer, liver dysfunction, infectious diseases, diabetic nephropathy, renal function, nephrotoxicity etc.

An Immunoassay is a biochemical test that measures the nearness or convergence of a macromolecule or a little particle in a solution using a counter acting agent (for the most part) or an antigen (some of the time). The particle identified by the Immunoassay is frequently alluded to as an "analyte" and is much of the time a protein, although it might be different sorts of atoms, of various size and sorts, if the best possible antibodies that have the sufficient properties for the test are created. Analytes in organic fluids, for example, serum or pee are oftentimes measured utilizing Immunoassays for restorative and research purposes. In vitro diagnostics which test an example of tissue or organic liquids, for example,

Microbiological culture, which decides the nearness or non-appearance of organisms in a specimen from the body, for the most part focused at recognizing pathogenic microorganisms. For example; Genetic testing, Blood Glucose, Liver Function Tests, Calcium test, Electrolytes in the blood, for example, Sodium, Potassium, Creatinine, and Urea.

  • Track 12-1: Immunoassays for IVD: ELISA, Multiplex assays, SELDI, LC/MS, Microarrays, Enzyme multiplied immunoassay technique (EMIT)Turbidimetric assays, Paramagnetic particle based assay, Chemi- Luminescent Immunoassay (CLIA), EIA, Fluorescent immunoassay (FIA), R
  • Track 12-2: Second generation Multiplex Immunoassays
  • Track 12-3: Automation of Multiplex Assays for Clinical Diagnosis
  • Track 12-4: Microfluidics and Polymer Lab-on-a-Chips
  • Track 12-5: High-Sensitivity Immunoassays for IVD Applications
  • Track 12-6: Errors reduction in Immunoassay Testing
  • Track 12-7: Nanoparticles-Based Naked-Eye Colorimetric Immunoassays for In Vitro Diagnostics